ALPRE.PA 3.64 (-1.62%)
FR0010169920Medical Diagnostics & ResearchDiagnostics & Research

Predilife (ALPRE.PA) Competitor Comparison

We are evaluating the key criteria listed to compare Predilife (ALPRE.PA) against its competitors in the Diagnostics & Research industry.

Linearity 10 years - ALPRE.PA ranking 0 / 58

These are the competitors of Predilife in the industry Diagnostics & Research ranked by linearity 10 years
1. Guardant Health GH
52.41
2. Ortho Clinical Diagnostics Holdings OCDX
33.4
3. National Research NRC
21.47
4. Anixa Biosciences ANIX
13.64
5. Illumina ILMN
11.11
6. Neogen NEOG
9.54
7. Olink Holding OLK
8.11
8. Inotiv NOTV
6.13
9. Sera Prognostics SERA
5.78
10. Global Cord Blood CO
5.67
11. Fulgent Genetics FLGT
5.46
12. DarioHealth DRIO
4.86
13. Sotera Health SHC
4.06
14. Pacific Biosciences of California PACB
4.02
15. Syneos Health SYNH
3.71
16. Bioventus BVS
3.6
17. Myriad Genetics MYGN
3.3
18. Co-Diagnostics CODX
3.21
19. Enzo Biochem ENZ
3.08
20. Exact Sciences EXAS
2.98
21. Qiagen QGEN
2.85
22. Psychemedics PMD
2.68
23. Exagen XGN
2.45
24. CareDx CDNA
2.32
25. Aspira Womens Health AWH
2.28
26. Twist Bioscience TWST
2.11
27. Meridian Bioscience VIVO
2.1
28. MDxHealth MDXH
2.03
29. Biodesix BDSX
1.96
30. NeoGenomics NEO
1.95
31. MaxCyte MXCT
1.92
32. bioAffinity Technologies BIAF
1.9
33. Personalis PSNL
1.89
34. Charles River Laboratories CRL
1.83
35. Prenetics Global PRE
1.77
36. Organovo Holdings ONVO
1.66
37. Neuronetics STIM
1.62
38. Quest Diagnostics DGX
1.62
39. Trinity Biotech TRIB
1.57
40. Laboratory Corp of America Holdings LH
1.43
41. SeqLL SQL
1.42
42. Interpace Biosciences IDXG
1.29
43. IQVIA Holdings IQV
1.23
44. Icon ICLR
1.17
45. PerkinElmer PKI
1.15
46. Precipio PRPO
1.09
47. Agilent Technologies A
0.98
48. DexCom DXCM
0.95
49. Mettler-Toledo MTD
0.89
50. Waters WAT
0.85
51. IDEXX Laboratories IDXX
0.84
52. Danaher DHR
0.79
53. Thermo Fisher Scientific TMO
0.78
54. Heska HSKA
0.52
55. Natera NTRA
0.44
56. RadNet RDNT
0.42
57. Lantheus Holdings LNTH
0.32
58. Medpace Holdings MEDP
0.22

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.